Related Experiment Video

Updated: Jun 12, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Gastrointestinal stromal tumor with primary resistance to imatinib and extensive bone metastases

Zeeshan Tariq1, Abhimanyu Ghose, Ehsan Rafiq

  • 1Department of Medicine, University of Toledo, Toledo, OH, USA. Zeeshan.tariq@utoledo.edu

American Journal of Therapeutics
|June 11, 2010
PubMed

Insights

Gastrointestinal stromal tumors (GISTs) can spread to bones, sometimes resisting imatinib treatment. Early bone metastasis detection and alternative therapies are crucial for managing advanced GISTs.

Area of Science:

  • Oncology
  • Gastroenterology
  • Medical Imaging

Background:

  • Gastrointestinal stromal tumors (GISTs) are the most common non-epithelial tumors of the GI tract, often driven by c-KIT or PDGFRA mutations.
  • Metastasis typically occurs in the liver and peritoneum, with bone involvement being rare.
  • Imatinib, a tyrosine kinase inhibitor, has significantly improved outcomes for advanced GISTs.

Observation:

  • This case highlights metastatic GISTs with extensive bone lesions.
  • The patient exhibited primary resistance to imatinib monotherapy.

Findings:

  • Bone metastases in GISTs, though uncommon, can present with primary imatinib resistance.
  • The study emphasizes the need for thorough imaging to detect bone involvement.

Implications:

  • Early identification of bone metastases is critical for effective GIST management.
  • Alternative therapeutic strategies are necessary to overcome imatinib resistance in GIST patients.
  • Further research into overcoming resistance mechanisms in metastatic GISTs is warranted.

More Related Videos

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...